NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 165 filers reported holding NOVOCURE LTD in Q2 2018. The put-call ratio across all filers is 0.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $246,510 | -48.8% | 5,940 | -25.8% | 0.00% | -40.0% |
| Q1 2023 | $481,300 | -34.4% | 8,003 | -20.0% | 0.01% | -44.4% |
| Q4 2022 | $734,013 | -4.2% | 10,007 | -0.7% | 0.01% | -10.0% |
| Q3 2022 | $766,000 | +20.6% | 10,079 | +10.3% | 0.01% | +25.0% |
| Q2 2022 | $635,000 | -18.2% | 9,138 | -2.4% | 0.01% | 0.0% |
| Q1 2022 | $776,000 | +74.4% | 9,366 | +58.0% | 0.01% | +60.0% |
| Q4 2021 | $445,000 | -49.3% | 5,926 | -21.6% | 0.01% | -50.0% |
| Q3 2021 | $878,000 | -21.7% | 7,561 | +49.4% | 0.01% | -23.1% |
| Q2 2021 | $1,122,000 | +134.2% | 5,060 | +39.6% | 0.01% | +116.7% |
| Q1 2021 | $479,000 | -47.1% | 3,624 | -30.7% | 0.01% | -57.1% |
| Q4 2020 | $905,000 | +125.1% | 5,231 | -37.3% | 0.01% | +100.0% |
| Q1 2019 | $402,000 | +69.6% | 8,342 | +17.8% | 0.01% | +40.0% |
| Q4 2018 | $237,000 | -31.5% | 7,082 | +7.2% | 0.01% | -16.7% |
| Q3 2018 | $346,000 | +64.8% | 6,604 | -1.3% | 0.01% | +50.0% |
| Q2 2018 | $210,000 | – | 6,694 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 470,884 | $39,681,000 | 20.12% |
| HARTLINE INVESTMENT CORP/ | 330,672 | $27,866,000 | 5.97% |
| MORGAN JESS S & CO INC | 52,889 | $4,457,000 | 4.37% |
| Darsana Capital Partners LP | 1,350,000 | $113,765,000 | 3.88% |
| Rhenman & Partners Asset Management AB | 350,000 | $29,495,000 | 3.23% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $843,000 | 2.55% |
| Taylor Frigon Capital Management LLC | 38,073 | $3,208,000 | 2.21% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 35,500 | $2,991,000 | 1.08% |
| Granite Investment Partners, LLC | 261,315 | $22,021,000 | 1.04% |
| Nicholas Investment Partners, LP | 85,835 | $7,233,000 | 0.74% |